Venous thromboembolism during neoadjuvant chemotherapy for ovarian cancer.
Samuel George OxleySarah AhmedKathryn BaxterDominic BlakeVictoria BradenMark R BrincatStacey BryanJames DilleyStephen DobbsAndrew A DurdenNana GomesBen JohnstonSonali KaushikFani KokkaMichelle LockleyJack Lowe-ZinolaRanjit ManchandaAiste McCormickCharlotte NottGemma Louise OwensAayushi PandyaJessica PrinceNeil RyanNicole RyanMichail SiderisSameera TannaJustin WatersNathan ZamesaMari ThomasAdeola OlaitanPublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2024)
Across a large, representative sample of UK gynecological cancer centers, one in five patients undergoing neoadjuvant chemotherapy were diagnosed with a potentially preventable venous thromboembolism, including one in nine diagnosed after commencing chemotherapy. This led to adverse clinical consequences for one third, including delay to oncological treatment and mortality. This high venous thromboembolism rate justifies the consideration of thromboprophylaxis in this patient group.
Keyphrases
- venous thromboembolism
- neoadjuvant chemotherapy
- locally advanced
- rectal cancer
- direct oral anticoagulants
- patients undergoing
- lymph node
- sentinel lymph node
- squamous cell carcinoma
- radiation therapy
- papillary thyroid
- cross sectional
- cardiovascular events
- type diabetes
- emergency department
- radical prostatectomy
- cardiovascular disease